Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{ec0e3d0fcb754720b460bd8f2f3c703d,
title = "Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis",
abstract = "Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).",
author = "Radstake, {T R D J} and M Svenson and Eijsbouts, {A M} and {van den Hoogen}, {F H J} and C Enevold and {van Riel}, {P L C M} and K Bendtzen",
year = "2009",
month = "11",
day = "1",
doi = "10.1136/ard.2008.092833",
language = "English",
volume = "68",
pages = "1739--45",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "11",

}

RIS

TY - JOUR

T1 - Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

AU - Radstake, T R D J

AU - Svenson, M

AU - Eijsbouts, A M

AU - van den Hoogen, F H J

AU - Enevold, C

AU - van Riel, P L C M

AU - Bendtzen, K

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).

AB - Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).

U2 - 10.1136/ard.2008.092833

DO - 10.1136/ard.2008.092833

M3 - Journal article

VL - 68

SP - 1739

EP - 1745

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 11

ER -

ID: 32255533